KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Deferred Revenue (2016 - 2025)

Sarepta Therapeutics has reported Current Deferred Revenue over the past 15 years, most recently at $443.4 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $443.4 million for Q4 2025, up 240.4% from a year ago — trailing twelve months through Dec 2025 was $443.4 million (up 240.4% YoY), and the annual figure for FY2025 was $443.4 million, up 240.4%.
  • Current Deferred Revenue for Q4 2025 was $443.4 million at Sarepta Therapeutics, down from $485.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SRPT hit a ceiling of $485.4 million in Q3 2025 and a floor of $22.5 million in Q3 2023.
  • Median Current Deferred Revenue over the past 5 years was $89.2 million (2021), compared with a mean of $138.0 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 74.79% in 2023 and later soared 464.6% in 2024.
  • Sarepta Therapeutics' Current Deferred Revenue stood at $89.2 million in 2021, then changed by 0.0% to $89.2 million in 2022, then tumbled by 43.51% to $50.4 million in 2023, then skyrocketed by 158.36% to $130.3 million in 2024, then skyrocketed by 240.4% to $443.4 million in 2025.
  • The last three reported values for Current Deferred Revenue were $443.4 million (Q4 2025), $485.4 million (Q3 2025), and $395.4 million (Q2 2025) per Business Quant data.